Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Jun 15;197(12):1662-8.
doi: 10.1086/588197.

Long-term persistence of mumps antibody after receipt of 2 measles-mumps-rubella (MMR) vaccinations and antibody response after a third MMR vaccination among a university population

Anand A Date  1 , Moe H Kyaw, Alison M Rue, Julie Klahn, Leann Obrecht, Terry Krohn, Josh Rowland, Steve Rubin, Thomas J Safranek, William J Bellini, Gustavo H Dayan
Affiliations

Long-term persistence of mumps antibody after receipt of 2 measles-mumps-rubella (MMR) vaccinations and antibody response after a third MMR vaccination among a university population

Anand A Date et al. J Infect Dis. .

Abstract

Background: High attack rates among vaccinated young adults reported during the 2006 mumps outbreak in the United States heightened concerns regarding mumps vaccine failure.

Methods: Serum specimens from university students and staff were tested for mumps immunoglobulin (Ig) G by enzyme immunoassay (EIA). A subset of participants vaccinated for < or =5 years and > or =15 years were tested by neutralizing antibody (NA) assay. Persons seronegative by EIA were offered a third dose of measles-mumps-rubella vaccine (MMR3), and serum specimens were obtained 7-10 days and 2-3 months after its administration.

Results: Overall, 94% (95% confidence interval [CI], 91%-96%) of the 440 participants were seropositive. No differences existed in seropositivity rates by sex, age, age at receipt of the second dose of MMR vaccine (MMR2), or time since receipt of MMR2 (P = .568). The geometric mean titer (GMT) of NA among persons vaccinated with MMR2 during the previous 1-5 years was 97 (95% CI, 64-148), whereas, among those vaccinated > or =15 years before blood collection, the GMT was 58 (95% CI, 44-76) (P = .065). After MMR3, 82% (14/17) and 91% (10/11) seroconverted in 7-10 days and 2-3 months, respectively.

Conclusions: Lower levels of NA observed among persons who received MMR2 > or =15 years ago demonstrates antibody decay over time. MMR3 vaccination of most seronegative persons marked the capacity to mount an anamnestic response.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest: none reported.

Figures

Figure 1.
Figure 1.
Prevalence of mumps seropositive EIA results and index standard ratio (ISR) values for mumps antibody among 440 university study participants, by years since receipt of a second dose of measlesmumps-rubella vaccine—Nebraska, 2006.
Figure 2.
Figure 2.
Geometric mean titers (GMTs) of mumps neutralizing antibody and index standard ratio (ISR) values for mumps antibody among 91 university study participants, by years since receipt of a second dose of measles-mumps-rubella vaccine—Nebraska, 2006.
Figure 3.
Figure 3.
Description of mumps seropositive results among 17 seronegative persons after receipt of a third dose of MMR (MMR3) vaccine—Nebraska, 2006. Indet, indeterminate. *All participants tested 2–3 months post MMR3 were IgM −
See this image and copyright information in PMC

References

    1. Galazka AM, Robertson SE, Kraigher A. Mumps and mumps vaccine: a global review. Bull World Health Organ 1999; 77:3–14. - PMC - PubMed
    1. Centers for Disease Control and Prevention. Recommendation of the Public Health Service Advisory Committee on Immunization Practices: mumps vaccine. MMWR Morb Mortal Wkly Rep 1977; 26:393–4.
    1. Centers for Disease Control and Prevention. Measles prevention: recommendations of the Immunization Practices Advisory Committee. MMWR Morb Mortal Wkly Rep 1989; 38 (Suppl 9):1–18. - PubMed
    1. Centers for Disease Control and Prevention. Summary of notifiable diseases—United States, 2003. MMWR 2005; 52:1–85. - PubMed
    1. Centers for Disease Control and Prevention. National, state, and urban area vaccination coverage levels among children aged 19–35 months—United States, 1999. MMWR Morb Mortal Wkly Rep 2000; 49:585–9. - PubMed

Publication types